发明公开
EP2819698A1 COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION
审中-公开
ALPHA-1抗胰蛋白酶联合治疗，和时间T细胞消耗用于抑制移植
- 专利标题： COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION
- 专利标题（中）： ALPHA-1抗胰蛋白酶联合治疗，和时间T细胞消耗用于抑制移植
-
申请号： EP13755285.7申请日： 2013-02-27
-
公开(公告)号： EP2819698A1公开(公告)日： 2015-01-07
- 发明人: LEWIS, Eli
- 申请人： Ben Gurion University of The Negev Research and Development Authority
- 申请人地址： P.O.Box 653 84105 Beer Sheva IL
- 专利权人： Ben Gurion University of The Negev Research and Development Authority
- 当前专利权人： Ben Gurion University of The Negev Research and Development Authority
- 当前专利权人地址： P.O.Box 653 84105 Beer Sheva IL
- 代理机构： MERH-IP Matias Erny Reichl Hoffmann
- 优先权： US201261603970P 20120228
- 国际公布： WO2013128381 20130906
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K38/55 ; A61P37/06
摘要：
The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (AAT) and temporary T-cell depletion including but not limited to anti-CD4 and anti-CD8 antibodies.
信息查询
